Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sayas

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Annals of Hematology|June 17, 2024
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?E U Suárez, B Boluda, E Lavilla, et al.
Transplantation and Cellular Therapy|February 16, 2025
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry ExperienceJosefina Serrano, David Martínez-Cuadrón, Cristina Gil, et al.
Cancer|April 10, 2026
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registryJuan M Alonso-Dominguez, Tamara Castaño-Bonilla, Cristina Gil, et al.
Blood Advances|November 18, 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry studyDavid Martínez-Cuadrón, Juan E Megías-Vericat, Josefina Serrano, et al.
Haematologica|November 12, 2020
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML projectClaudia Sargas, Rosa Ayala, María Carmen Chillón, et al.
Cancers|June 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid LeukemiaDavid Martínez-Cuadrón, Josefina Serrano, José Mariz, et al.
Leukemia Research|December 24, 2025
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratoriesMargarida Coucelo, Claudia Sargas, Rosa Ayala, et al.
Cancers|March 13, 2025
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Rebeca Rodriguez-Veiga, Claudia Sargas, et al.
Leukemia|September 1, 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registryAna Alfonso-Pierola, David Martinez-Cuadrón, Rebeca Rodríguez-Veiga, et al.
American Journal of Hematology|April 22, 2026
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA StudyGaspar Aspas Requena, Rebeca Rodríguez-Veiga, Cristina Gil, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Annals of Hematology|June 17, 2024
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?E U Suárez, B Boluda, E Lavilla, et al.
Transplantation and Cellular Therapy|February 16, 2025
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry ExperienceJosefina Serrano, David Martínez-Cuadrón, Cristina Gil, et al.
Cancer|April 10, 2026
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registryJuan M Alonso-Dominguez, Tamara Castaño-Bonilla, Cristina Gil, et al.
Blood Advances|November 18, 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry studyDavid Martínez-Cuadrón, Juan E Megías-Vericat, Josefina Serrano, et al.
Haematologica|November 12, 2020
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML projectClaudia Sargas, Rosa Ayala, María Carmen Chillón, et al.
Cancers|June 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid LeukemiaDavid Martínez-Cuadrón, Josefina Serrano, José Mariz, et al.
Leukemia Research|December 24, 2025
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratoriesMargarida Coucelo, Claudia Sargas, Rosa Ayala, et al.
Cancers|March 13, 2025
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Rebeca Rodriguez-Veiga, Claudia Sargas, et al.
Leukemia|September 1, 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registryAna Alfonso-Pierola, David Martinez-Cuadrón, Rebeca Rodríguez-Veiga, et al.
American Journal of Hematology|April 22, 2026
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA StudyGaspar Aspas Requena, Rebeca Rodríguez-Veiga, Cristina Gil, et al.
Pageof 3